Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $112,392.06 in Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,673 shares of Candel Therapeutics stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $8.22, for a total transaction of $112,392.06. Following the transaction, the insider now directly owns 124,207 shares of the company’s stock, valued at approximately $1,020,981.54. This trade represents a 9.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Candel Therapeutics Trading Down 6.3 %

Shares of NASDAQ:CADL opened at $8.18 on Friday. The stock has a market cap of $265.65 million, a PE ratio of -4.73 and a beta of -1.20. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 1.66. Candel Therapeutics, Inc. has a 12-month low of $1.16 and a 12-month high of $14.60. The business has a 50 day moving average of $6.37 and a 200-day moving average of $6.22.

Institutional Trading of Candel Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Candel Therapeutics during the second quarter worth $338,000. Geode Capital Management LLC increased its position in Candel Therapeutics by 12.8% during the third quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock worth $3,112,000 after acquiring an additional 51,111 shares during the period. Cubist Systematic Strategies LLC bought a new position in Candel Therapeutics during the second quarter worth about $162,000. Rhumbline Advisers acquired a new stake in Candel Therapeutics in the 2nd quarter worth about $143,000. Finally, Barclays PLC grew its position in shares of Candel Therapeutics by 327.1% during the 3rd quarter. Barclays PLC now owns 28,688 shares of the company’s stock worth $199,000 after purchasing an additional 21,971 shares in the last quarter. 13.93% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price (up previously from $11.00) on shares of Candel Therapeutics in a report on Wednesday, December 18th.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.